Fate Therapeutics, Inc. provided earnings guidance for the year 2023. For each of the remaining three quarters of 2023, the Company expects to recognize approximately $0.8 million in revenue under the ONO collaboration in connection with its conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.22 USD | +1.69% | +8.76% | +12.83% |
05-10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
05-10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.83% | 480M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.46% | 21.25B | |
-5.85% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023